Not that I disagree with the strategy. I'm all for the opportunity. But this is G's way of telling us Lympro will get us a fraction of Todos, not 49.99%. I 'm ok with that. A year or so ago, Lympro was merely a painful memory, now, it'll be 15-20% of something, something that's grown too. That's good.
We're still here, we still have opportunities, and our largest Legacy Debt Holders are practically bankrupt convicts.
(1)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links